ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer.
Rodney P RocconiLaura StanberyMin TangLuciana Madeira da SilvaAdam WalterBradley J MonkThomas J HerzogRobert L ColemanLuisa ManningGladice WallravenStaci HorvathErnest BognarNeil SenzerScott BrunJohn J NemunaitisPublished in: Communications medicine (2022)
NSA should be considered for application to investigational targeted therapies in order to identify populations most likely to benefit from treatment, in preparation for efficacy conclusive trials.